Phosphorous Magnetic Resonance Spectroscopy and Molecular Markers in IDH1 Wild Type Glioblastoma.

Autor: Galijašević M; Department of Neuroradiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.; Neuroimaging Research Core Facility, Medical University of Innsbruck, 6020 Innsbruck, Austria., Steiger R; Department of Neuroradiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.; Neuroimaging Research Core Facility, Medical University of Innsbruck, 6020 Innsbruck, Austria., Radović I; Department of Neuroradiology, Medical University of Innsbruck, 6020 Innsbruck, Austria., Birkl-Toeglhofer AM; Institute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, 6020 Innsbruck, Austria., Birkl C; Department of Neuroradiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.; Neuroimaging Research Core Facility, Medical University of Innsbruck, 6020 Innsbruck, Austria., Deeg L; Department of Neuroradiology, Medical University of Innsbruck, 6020 Innsbruck, Austria., Mangesius S; Department of Neuroradiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.; Neuroimaging Research Core Facility, Medical University of Innsbruck, 6020 Innsbruck, Austria., Rietzler A; Department of Neuroradiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.; Neuroimaging Research Core Facility, Medical University of Innsbruck, 6020 Innsbruck, Austria., Regodić M; Department of Otorhinolaryngology, Medical University of Innsbruck, 6020 Innsbruck, Austria.; Department of Radiation Oncology, Medical University of Vienna, 1010 Vienna, Austria., Stockhammer G; Department of Neurology, Medical University of Innsbruck, 6020 Innsbruck, Austria., Freyschlag CF; Department of Neurosurgery, Medical University of Innsbruck, 6020 Innsbruck, Austria., Kerschbaumer J; Department of Neurosurgery, Medical University of Innsbruck, 6020 Innsbruck, Austria., Haybaeck J; Institute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, 6020 Innsbruck, Austria.; Diagnostic and Research Center for Molecular Biomedicine, Institute of Pathology, Medical University of Graz, 8010 Graz, Austria., Grams AE; Department of Neuroradiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.; Neuroimaging Research Core Facility, Medical University of Innsbruck, 6020 Innsbruck, Austria., Gizewski ER; Department of Neuroradiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.; Neuroimaging Research Core Facility, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2021 Jul 16; Vol. 13 (14). Date of Electronic Publication: 2021 Jul 16.
DOI: 10.3390/cancers13143569
Abstrakt: The World Health Organisation's (WHO) classification of brain tumors requires consideration of both histological appearance and molecular characteristics. Possible differences in brain energy metabolism could be important in designing future therapeutic strategies. Forty-three patients with primary, isocitrate dehydrogenase 1 (IDH1) wild type glioblastomas (GBMs) were included in this study. Pre-operative standard MRI was obtained with additional phosphorous magnetic resonance spectroscopy (31-P-MRS) imaging. Following microsurgical resection of the tumors, biopsy specimens underwent neuropathological diagnostics including standard molecular diagnosis. The spectroscopy results were correlated with epidermal growth factor (EGFR) and O6-Methylguanine-DNA methyltransferase (MGMT) status. EGFR amplified tumors had significantly lower phosphocreatine (PCr) to adenosine triphosphate (ATP)-PCr/ATP and PCr to inorganic phosphate (Pi)-PCr/Pi ratios, and higher Pi/ATP and phosphomonoesters (PME) to phosphodiesters (PDE)-PME/PDE ratio than those without the amplification. Patients with MGMT-methylated tumors had significantly higher cerebral magnesium (Mg) values and PME/PDE ratio, while their PCr/ATP and PCr/Pi ratios were lower than in patients without the methylation. In survival analysis, not-EGFR-amplified, MGMT-methylated GBMs showed the longest survival. This group had lower PCr/Pi ratio when compared to MGMT-methylated, EGFR-amplified group. PCr/Pi ratio was lower also when compared to the MGMT-unmethylated, EGFR not-amplified group, while PCr/ATP ratio was lower than all other examined groups. Differences in energy metabolism in various molecular subtypes of wild-type-GBMs could be important information in future precision medicine approach.
Databáze: MEDLINE
Externí odkaz: